Advertisement

Hematologic Disorders in Renal Failure

  • K. M. Koch

Abstract

Even though renal failure also affects the function of white blood cells and thrombocytes (1), renal anemia is the only hematologic disturbance of uremia for which well-founded possibilities of therapeutic intervention exist today. The basis for this exceptional and fortunate situation is our advanced understanding of the pathogenesis of renal anemia as well as recent progress in molecular biology. As this book is devoted to therapy, this chapter will restrict itself to renal anemia and its management.

Keywords

Continuous Ambulatory Peritoneal Dialysis Recombinant Human Erythropoietin Renal Anemia Nandrolone Decanoate Terminal Renal Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eschbach JW: Hematologic problems of dialysis patients. In: Drukker, Parsons, Maher, eds, Replacement of Renal Function by Dialysis. Martinus Nijhoff, Boston, pp 630–645, 1983.Google Scholar
  2. 2.
    Neff MS, Kim KE, Persoff M, Onesti G, Swartz C: Hemodynamics of uremic anemia. Circulation 43:876–883, 1971.PubMedGoogle Scholar
  3. 3.
    Eschbach JW, Adamson JW: Anemia of end-stage renal disease. Kidney Int 28:1–5, 1985.PubMedCrossRefGoogle Scholar
  4. 4.
    Bogin E, Massry SG, Levi J, Mdaldeti M, Bristol G, Smith J: Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 69:1017–1025, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Akmal M, Telfer N, Ansari AN, Massry SG: Red blood cell survival in chronic renal failure: Role of secondary hyperparathyroidism. J Clin Invest 76:1695–1698, 1985.CrossRefGoogle Scholar
  6. 6.
    Jacob HS, Amsden T: Acute hemolytic anemia with rigid red cells in hypophosphatemia. N Engl J Med 285:1146–1450, 1071.Google Scholar
  7. 7.
    Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP: Radioimmunoassay of erythropoietin: Circulating levels in normal and polycythemic human beings. J Lab Clin Med 99:624–635, 1982.PubMedGoogle Scholar
  8. 8.
    McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437–444, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Caro J, Brown S, Miller O, Murray T, Erslev AJ: Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93:449–458, 1979.PubMedGoogle Scholar
  10. 10.
    Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM: Serum erythropoietin concentration in chronic renl failure: Relationship to degree of anemia and excretory renal function. Blood 54:877–884, 1979.PubMedGoogle Scholar
  11. 11.
    Eschbach JW, Adamson JW, Cook JD: Disorders of red blood cell production in uremia. Arch Intern Med 126:812–815, 1970.PubMedCrossRefGoogle Scholar
  12. 12.
    Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM: Improving anemia by hemodialysis: Effect on serum erythropoietin. Kidney Int 17:382–387, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Radtke HW, Rege AB, LaMarche MB, Bartos D, Bartos F, Campbell RA, Fisher JW: Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 67:1623–1629, 1981.PubMedCrossRefGoogle Scholar
  14. 14.
    Meytes D, Bogin E, Ma A, Dukes PP, Massry SG: Effect of parathyroid hormone on erythropoiesis. J Clin Invest 67:1263–1269, 1981.PubMedCrossRefGoogle Scholar
  15. 15.
    Segal GM, Stueve T, Adamson JW: Spermine and spermidine are non-specific inhibitors of in vitro hematopoiesis. Kidney Int 31:72–76, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    Kaiser L, Schwartz KA: Aluminum-induced anemia. Am J Kidney Dis 6:348–352, 1985.PubMedGoogle Scholar
  17. 17.
    Swartz R, Dombrouski J, Burnatowska — Hledin M, Mayor G: Microcytic anemia in dialysis patients: Reversible marker of aluminium toxicity. Am J Kidney Dis 9:217–223, 1987.PubMedGoogle Scholar
  18. 18.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73–78, 1987.CrossRefGoogle Scholar
  19. 19.
    Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2:1175–1177, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Duling BR, Pittman RN: Oxygen tension: Dependent or independent variable in local control of blood flow? Fed Proc 34(11):2012–2019, 1975.PubMedGoogle Scholar
  21. 21.
    Bommer J, Müller-Bühl E, Ritz E, Eifert J: Recombinant human erythropoietin in anaemic patients on haemodialysis (letter). Lancet 1:392, 1987.PubMedCrossRefGoogle Scholar
  22. 22.
    Wideröe TE, Sanengen T, Halvorsen S: Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis. Kidney Int 24:208–217, 1983.Google Scholar
  23. 23.
    Chandra M, McVicar M, Clemons G, Mossey RT, Wilkes BM: Role of erythropoietin in the reversal of anemia of renal failure with continuous ambulatory peritoneal dialysis. Nephron 46:312–315, 1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N: A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 304:871–875, 1981.CrossRefGoogle Scholar
  25. 25.
    Hendler ED, Solomon L: Androgen therapy in hemodialysis patients: I. Effects on red cell oxygen transport. Kidney Int 31:100–106, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • K. M. Koch

There are no affiliations available

Personalised recommendations